<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The aim of this study was to determine the most cost-effective time point for initiation of <z:chebi fb="0" ids="5959">irbesartan</z:chebi> treatment in hypertensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: This study was a Markov model-simulated progression from <z:mp ids='MP_0002959'>microalbuminuria</z:mp> to overt <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, doubling of serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>, <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo>, and <z:hpo ids='HP_0011420'>death</z:hpo> in hypertensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Two <z:chebi fb="0" ids="5959">irbesartan</z:chebi> strategies were created: early <z:chebi fb="0" ids="5959">irbesartan</z:chebi> 300 mg daily (initiated with <z:mp ids='MP_0002959'>microalbuminuria</z:mp>) and late <z:chebi fb="0" ids="5959">irbesartan</z:chebi> (initiated with overt <z:hpo ids='HP_0000112'>nephropathy</z:hpo>) </plain></SENT>
<SENT sid="3" pm="."><plain>These strategies were compared with control, which consisted of <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy with standard medications (excluding <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi>, other angiotensin-2 receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi>, and <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> <z:chebi fb="0" ids="38215">calcium channel blockers</z:chebi>) with comparable blood pressure control, initiated at <z:mp ids='MP_0002959'>microalbuminuria</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Transition probabilities were taken from the <z:chebi fb="0" ids="5959">Irbesartan</z:chebi> in Reduction of <z:mp ids='MP_0002959'>Microalbuminuria</z:mp>-2 study, <z:chebi fb="0" ids="5959">Irbesartan</z:chebi> in Diabetic <z:hpo ids='HP_0000112'>Nephropathy</z:hpo> Trial, and other published sources </plain></SENT>
<SENT sid="5" pm="."><plain>Costs and life expectancy, discounted at 3% yearly, were projected over 25 years for 1,000 simulated patients using a third-party payer perspective in a U.S. setting </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Compared with control, early and late <z:chebi fb="0" ids="5959">irbesartan</z:chebi> treatment in 1,000 patients were projected to save (mean +/- SD) 11.9 +/- 3.3 million dollars and 3.3 +/- 2.7 million dollars, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Early use of <z:chebi fb="0" ids="5959">irbesartan</z:chebi> added 1,550 +/- 270 undiscounted life-years (discounted 960 +/- 180), whereas late <z:chebi fb="0" ids="5959">irbesartan</z:chebi> added 71 +/- 40 life-years (discounted 48 +/- 27) in 1,000 patients </plain></SENT>
<SENT sid="8" pm="."><plain>Early <z:chebi fb="0" ids="5959">irbesartan</z:chebi> treatment was superior under a wide-range of plausible assumptions </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Early <z:chebi fb="0" ids="5959">irbesartan</z:chebi> treatment was projected to improve life expectancy and reduce costs in hypertensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:mp ids='MP_0002959'>microalbuminuria</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Later use of <z:chebi fb="0" ids="5959">irbesartan</z:chebi> in overt <z:hpo ids='HP_0000112'>nephropathy</z:hpo> is also superior to standard care, but <z:chebi fb="0" ids="5959">irbesartan</z:chebi> should be started earlier and continued long term </plain></SENT>
</text></document>